Recent Finacing
Recent Raise
Amylyx Pharmaceuticals (Cambridge, MA) develops AMX0035, a fixed‑dose sodium phenylbutyrate/taurursodiol combination targeting ER and mitochondrial degeneration pathways to reduce neuronal death; conducting ALS and Alzheimer’s trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
